Wire · opportunities
America Is About to Go Over a Peptide Cliff
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
An FDA advisory committee voted to allow compounding pharmacies to produce BPC-157, a peptide with minimal human safety data and no standard approval process, despite FDA researchers citing weak evidence and unknown safety profiles. The decision opens a path for telehealth and wellness companies to sell peptides legally that have previously been sourced from unregulated grey-market vendors.
This Wire brief tracks EternaFusion, and It sits within Fusion42's coverage of Digital Health, and 9 sources have reported it between 23 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
If you run telehealth or direct-to-consumer wellness, you can now sell peptides with FDA blessing—but only through compounding pharmacies, and without the safety data or liability shield a normal drug approval would give you. Move fast: advisory votes are not final, but the window to build the distribution and clinical story closes when the FDA codifies rules.
◆ Mentioned in this story
◆ Coverage
9 sources · first reported 23 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics